The publication of the UK National Institute for Health and Clinical Excellence familial hypercholesterolaemia guideline led to a combined meeting of lipidologists and geneticists in Scotland. It was agreed to implement a system of cascade screening for familial heterozygous hypercholesterolaemia based on genetic testing to identify family members of known cases who have not previously been diagnosed and treated. The cascade screening system for familial heterozygous hypercholesterolaemia Scotland is described herein.
Weirzbicki AS , Humphries SE, Minhas R.Familial hypercholesterolaemia: summary of NICE guidance. BMJ2008;337:509-11.
2.
CG71 Familial hypercholesterolaemia: NICE guideline. London : NICE, 2008. www.nice.org.uk/Guidance/CG71/NiceGuidance/pdf/English (Accessed 14 December 2009)
3.
Thannhauser SJ, Magendantz H.The different clinical groups of xanthomatous diseases: a clinical physiological study of 22 cases. Ann Intern Med1938;11:1662-3.
4.
Müller C.Xanthomata, hypercholesterolemia, angina pectoris . Acta Med Scand1938;89:75-84.
5.
Goldstein JL , Brown MSFamilial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol . Proc Natl Acad Sci U S A1973;70):2804-8.
6.
Marks D., Thorogood M., Farrer JM, Humphries S.Census of clinics providing specialist lipid services in the United Kingdom . J Public Health (Oxf) 2004;26:353-4.
7.
Neil A., Hammond T., Huxley R. et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ2000;321:148.
8.
Scientific Steering Committee on behalf of the Simon Broome Study Group.Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ1991;303:893-6.
9.
Gallagher JJ , Myant N.The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein B-100. Atherosclerosis1995;115:263-72.
10.
Varret M., Rabies J.-P. Sait-Jore B. et al. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p. Am J Hum Genet1999;64:1378-87.
11.
Gray J., Jaiyeola A., Whiting M. et al. Identifying patients with familial hypercholesterolaemia in primary care: an infomatics-based approach in one primary care centre. Heart2008;94:754-8.
12.
Scientific Steering Committee on behalf of the Simon Broome Study Group.Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis1999;142: 105-12.
13.
Neil A., Cooper J., Betteridge J. et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J2008;29:2625-33.
14.
Newson AJ, Humphries SECascade testing in familial hypercholesterolaemia: how should family members be contacted?Eur J Hum Genet2005 ;13:401-8.
15.
Marks D., Wonderling D., Thorogood M. et al. Cost effectiveness of different approaches of screening for familial hypercholesterolaemia. BMJ2002;324:1-6.
